Abstract Background Trimethylamine N-oxide (TMAO) derived from gut microbiota causes
kidney-heart damage in chronic kidney disease (CKD) patients. However, it is controversial …

Elevated circulating trimethylamine N-oxide (TMAO) concentrations have been observed in
patients with chronic kidney disease (CKD). We aimed to systematically estimate and …

Rationale: Trimethylamine-N-oxide (TMAO), a gut microbial-dependent metabolite of dietary
choline, phosphatidylcholine (lecithin), and l-carnitine, is elevated in chronic kidney …

Background The microbial metabolite Trimethylamine-N-oxide (TMAO) has been linked to
adverse cardiovascular outcome and mortality in the general population. Objective To …

Patients with chronic kidney disease (CKD) have an enhanced risk of cardiovascular (CV)
morbidity and mortality when compared with age-and gender-matched individuals with …

Background Trimethylamine-N-oxide (TMAO) is expected to be a prognostic biomarker
among patients suffering from chronic kidney disease (CKD). However, investigations on the …

Abstract Trimethylamine-N-Oxide (TMAO) is a microbiome-related metabolite that is cleared
by the kidney and linked to renal function. We explored the relationship between TMAO and …

Abstract Purpose of Review Trimethylamine N-oxide (TMAO) is a gut microbiota-dependent
metabolite produced from choline and phosphatidylcholine. Trimethylamine N-oxide was …

The profile of gut microbiota can vary according to host genetic and dietary characteristics,
and be influenced by disease state and environmental stressors. The uremic dysbiosis …

Gut microbiota-dependent Trimethylamine-N-oxide (TMAO) has been reported to be strongly
linked to renal function and to increased cardiovascular events in the general population …